Piperazines
"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D010879
|
MeSH Number(s) |
D03.383.606
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in UAMS Profiles by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 1 | 1 | 2 | 2022 | 0 | 4 | 4 | 2021 | 1 | 2 | 3 | 2020 | 1 | 1 | 2 | 2019 | 2 | 0 | 2 | 2018 | 3 | 1 | 4 | 2017 | 2 | 1 | 3 | 2016 | 2 | 0 | 2 | 2015 | 1 | 1 | 2 | 2014 | 2 | 2 | 4 | 2013 | 5 | 4 | 9 | 2012 | 2 | 0 | 2 | 2011 | 3 | 1 | 4 | 2010 | 2 | 2 | 4 | 2009 | 3 | 3 | 6 | 2008 | 2 | 3 | 5 | 2007 | 4 | 3 | 7 | 2006 | 7 | 0 | 7 | 2005 | 2 | 1 | 3 | 2004 | 1 | 2 | 3 | 2003 | 2 | 1 | 3 | 2002 | 1 | 0 | 1 | 2000 | 2 | 0 | 2 | 1998 | 1 | 0 | 1 | 1996 | 0 | 1 | 1 | 1995 | 1 | 1 | 2 | 1994 | 3 | 0 | 3 | 1990 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Piperazines" by people in Profiles over the past ten years.
-
Bhandari SK, Wiest N, Sallmyr A, Du R, Tomkinson AE. Redundant but essential functions of PARP1 and PARP2 in DNA ligase I-independent DNA replication. Nucleic Acids Res. 2024 Sep 23; 52(17):10341-10354.
-
Chandler CM, Nickell JR, George Wilson A, Culver JP, Crooks PA, Bardo MT, Dwoskin LP. Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats. Biochem Pharmacol. 2024 10; 228:116189.
-
Shebl B, Ng D, Lalazar G, Rosemore C, Finkelstein TM, Migler RD, Zheng G, Zhang P, Jiang CS, Qureshi A, Vaughan R, Yarchoan M, de Jong YP, Rice CM, Coffino P, Ortiz MV, Zhou D, Simon SM. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. JCI Insight. 2022 09 08; 7(17).
-
Keisner SV. Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy. J Oncol Pharm Pract. 2022 Oct; 28(7):1624-1633.
-
Coralic Z, Rader ES, Vinson DR, Wilson MP. Haloperidol Versus Ziprasidone With Concomitant Medications and Other Predictors of Physical Restraint Duration in the Emergency Department. J Emerg Med. 2022 05; 62(5):636-647.
-
Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol. 2022 03 09; 15(1):23.
-
Aytatli A, Barlak N, Sanli F, Caglar HO, Gundogdu B, Tatar A, Ittmann M, Karatas OF. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cell Oncol (Dordr). 2022 Feb; 45(1):41-56.
-
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Mol Cancer Ther. 2022 01; 21(1):184-192.
-
Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci U S A. 2021 04 13; 118(15).
-
Tripathi H, Al-Darraji A, Abo-Aly M, Peng H, Shokri E, Chelvarajan L, R Donahue R, Levitan BM, Gao E, Hernandez G, Morris AJ, Smyth SS, Abdel-Latif A. Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction. J Mol Cell Cardiol. 2020 12; 149:95-114.
-
He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020 07 16; 13(1):95.
-
Al-Oudat BA, Ramapuram H, Malla S, Audat SA, Hussein N, Len JM, Kumari S, Bedi MF, Ashby CR, Tiwari AK. Novel Chrysin-De-Allyl PAC-1 Hybrid Analogues as Anticancer Compounds: Design, Synthesis, and Biological Evaluation. Molecules. 2020 Jul 04; 25(13).
-
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
-
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
-
Harada Y, Virmani T, Gokden M, Stefans V. Toxic Myopathy due to Antidopaminergic Medication Without Neuroleptic Malignant Syndrome. J Clin Neuromuscul Dis. 2018 Dec; 20(2):94-98.
-
Manzano M, Patil A, Waldrop A, Dave SS, Behdad A, Gottwein E. Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma. Nat Commun. 2018 08 15; 9(1):3263.
-
Delgado M, Chambers TC. Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase. Cell Cycle. 2018; 17(14):1784-1796.
-
Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703.
-
Dang NL, Hughes TB, Miller GP, Swamidass SJ. Computationally Assessing the Bioactivation of Drugs by N-Dealkylation. Chem Res Toxicol. 2018 02 19; 31(2):68-80.
-
Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2017 12 15; 27(24):5467-5472.
-
Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, Jones D, George TJ, Hromas R. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017 Oct; 80(4):861-867.
-
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518.
-
Kucab JE, Hollstein M, Arlt VM, Phillips DH. Nutlin-3a selects for cells harbouring TP53 mutations. Int J Cancer. 2017 02 15; 140(4):877-887.
-
Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 09 15; 26(18):4441-4445.
-
Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 10; 34(10):1716-1724.
-
Nairooz R, Sardar P, Aronow WS. Not All NSTEMIs Are Created Equal. J Am Coll Cardiol. 2015 Apr 28; 65(16):1718.
-
Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. Bioorg Med Chem. 2015 May 15; 23(10):2328-43.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|